References
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 2018; 68: 394-24. doi: 10.3322/caac.21492
- Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018; 103: 356-87. doi: 10.1016/j.ejca.2018.07.005
- Attard G, Parker C, Eeles R, Schröder F, Tomlins S, Tannock I, et al. Prostate cancer. Lancet 2016; 387: 70-82. doi: 10.1016/S0140-6736(14)61947-4
- Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends – an update. Cancer Epidemiol Biomarkers Prev 2016; 25: 16-27. doi: 10.1158/1055-9965
- Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014; 65: 124-37. doi: 10.1016/j.eururo.2013.09.046
- Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2016; 375: 1425-37. doi: 10.1056/NEJMoa1606221
- Hamdy FC, Donovan JL, Lane JA. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016; 375: 1415-24. doi: 10.1056/NEJMoa1606220
- Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999; 43: 1095-101. doi: 10.1016/s0360-3016(98)00438-6
- Arcangeli S, Greco C. Hypofractionated radiotherapy for organ-confined prostate cancer: is less more? Nat Rev Urol 2016; 13: 400-8. doi: 10.1038/nrurol.2016.106
- Zaorsky NG, Studenski MT, Dicker AP, Gomella L, Den R. Stereotactic body radiation therapy for prostate cancer: is the technology ready to be the standard of care? Cancer Treat Rev 2013; 39: 212-8. doi: 10.1016/j.ctrv.2012.10.003
- Dearnaley D, Syndikus I, Mossop H, Bidmead M, Bloomfield D, Clark C, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 2016; 17: 1047-60. doi: 10.1016/S1470-2045(16)30102-4
- Catton CN, Lukka H, Gu CS, Martin J, Supiot S, Chung P, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol 2017; 35: 1884-90. doi: 10.1200/JCO.2016.71.7397
- Lee WR, Dignam JJ, Amin MB, Bruner D, Low D, Swanson G, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol 2016; 34: 2325-32. doi: 10.1200/JCO.2016.67.0448
- Aluwini S, van Rooij P, Hoogeman M, Kirkels W, Kolkman-Deurloo I, Bangma C. Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results. Radiat Oncol Lond Engl 2013; 8: 84. doi: 10.1186/1748-717X-8-84
- Loblaw A, Cheung P, D’Alimonte L, Deabreu A, Mamedov A, Zhang L, et al. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. Radiother Oncol J Eur Soc Ther Radiol Oncol 2013; 107: 153-8. doi: 10.1016/j.radonc.2013.03.022
- King CR, Brooks JD, Gill H, Presti Jr J. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012; 82: 877-82. doi: 10.1016/j.ijrobp.2010.11.054
- Jorgo K, Ágoston P, Szabó Z, Major T, Polgár Cs. [Use of gold radionuclide markers implanted into the prostate for image-guided radiotherapy in prostate cancer: side effects caused by the marker implantation]. [Hungarian]. Magy Onkol 2014; 58: 182-87.
- Jorgo K, Agoston P, Major T, Takácsi-Nagy Z, Polgár Cs. Transperineal gold marker implantation for image-guided external beam radiotherapy of prostate cancer. A single institution, prospective study. Strahlenther Onkol 2017; 193: 452-58. doi: 10.1007/s00066-017-1104-2.
- D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen M. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003; 21: 2163-72. doi: 10.1200/JCO.2003.01.075
- Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 30: 1341-46. doi: 10.1016/0360-3016(95)00060-C
- Holmboe ES, Concato J. Treatment decisions for localized prostate cancer: asking men what’s important. J Gen Intern Med 2000; 15: 694-701. doi: 10.1046/j.1525-1497.2000.90842.x
- Dandapani SV, Sanda MG. Measuring health-related quality of life consequences from primary treatment for early-stage prostate cancer. Semin Radiat Oncol 2008; 18: 67-72. doi: 10.1016/j.semradonc.2007.10.001
- Hodges JC, Lotan Y, Boike TP, Benton R, Barrier A, Timmerman R. Cost-effectiveness analysis of SBRT versus IMRT: an emerging initial radiation treatment option for organ-confined prostate cancer. Am J Manag Care 2012; 18: e186-93. doi: 10.1200/JOP.2012.000548
- Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 2019; 20: 1531-43. doi: 10.1016/S1470-2045(19)30569-8
- Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 2019; 394: 385-95. doi: 10.1016/S0140-6736(19)31131-6
- Madsen BL, Hsi RA, Pham HT, Fowler J, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007; 67: 1099-105. doi: 10.1016/j.ijrobp.2006.10.050
- Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M, et al. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol 2010; 10: 1. doi: 10.1186/1471-2490-10-1
- Boike TP, Lotan Y, Cho LC, Brindle J, DeRose P, Xie X, et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol 2011; 29: 2020-26. doi: 10.1200/JCO.2010.31.4377
- Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol 2011; 6: 3. doi: 10.1186/1748-717X-6-3
- Jabbari S, Weinberg VK, Kaprealian T, Hsu I, Ma L, Chuang C, et al. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys 2012; 82: 228-34. doi: 10.1016/j.ijrobp.2010.10.026
- McBride SM, Wong DS, Dombrowski JJ, Harkins B, Tapella P, Hanscom H, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 2012; 118: 3681-90. doi: 10.1002/cncr.26699
- Bolzicco G, Favretto MS, Satariano N, Scremin E, Tambone C, Tasca A. A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy. BMC Urol 2013; 13: 49. doi: 10.1186/1471-2490-13-49
- Oliai C, Lanciano R, Sprandio B, Yang J, Lamond J, Arrigo S, et al. Stereotactic body radiation therapy for the primary treatment of localized prostate cancer. J Radiat Oncol 2013; 2: 63-70. doi: 10.1007/s13566-012-0067-2
- Mantz C. A Phase II trial of stereotactic ablative body radiotherapy for low-risk prostate cancer using a non-robotic linear accelerator and realtime target tracking: Report of toxicity, quality of life, and disease control outcomes with 5-year minimum follow-up. Front Oncol 2014; 4: 279. doi: 10.3389/fonc.2014.00279
- Chen LN, Suy S, Wang H, Bhagat A, Woo J, Moures R, et al. Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer. Radiat Oncol 2014; 9: 148. doi: 10.1186/1748-717X-9-148
- Anwar M, Weinberg V, Seymour Z, Hsu J, Roach M 3rd, Gottschalk A. Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer. Radiat Oncol 2016; 11: 8. doi: 10.1186/s13014-016-0585-y
- Hannan R, Tumati V, Xie XJ, Cho LC, Kavanagh B, Brindle J, et al. Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial. Eur J Cancer 2016; 59: 142-51. doi: 10.1016/j.ejca.2016.02.014
- Murthy V, Sinha S, Kannan S, Datta D, Das R, Bakshi G, et al. Safety of prostate stereotactic body radiation therapy after Transurethral Resection of Prostate (TURP): A propensity score matched pair analysis. Pract Radiat Oncol 2019; 5: 347-53. doi: 10.1016/j.prro.2019.04.003
- Wang K, Chen RC, Kane B, Medbery C, Underhill K, Gray J, et al. Patient and dosimetric predictors of genitourinary and bowel quality of life after prostate SBRT: Secondary analysis of a multi-institutional trial. Int J Radiat Oncol Biol Phys 2018; 102: 1430-37. doi: 10.1016/j.ijrobp.2018.07.191
- Bolzicco G, Favretto MS, Satariano N, Scremin E, Tambone C, Tasca A. A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy. BMC Urol 2013; 13: 49. doi: 10.1186/1471-2490-13-49
- Katz AJ, Kang J. Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study. Front Oncol 2014; 4: 301. doi: 10.3389/ fonc.2014.00301
- Gurka MK, Chen LN, Bhagat A, Moures R, Kim SJ, Yung T, et al. Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer. Radiat Oncol 2015; 10: 44. doi: 10.1186/s13014-015-0351-6